Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT04831450 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT04831450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04831450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2022
Completion date
July 15, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, hnscc, squamous cell carcinoma of hypopharynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the oral cavity